Biofrontera is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products focused on the fields of photodynamic therapy and topical antibiotics. In collaboration with healthcare providers, we are fully committed to advancing treatment options and patient care.
Biofrontera, Inc. was founded in March 2015 to commercialize the FDA-approved flagship drug Ameluz® (aminolevulinic acid hydrochloride) gel, 10%, in the United States. In 2019, Biofrontera Inc. expanded its U.S.-product portfolio with the FDA-approved drug Xepi® (ozenoxacin) cream, 1%. With both FDA-approved products, Biofrontera Inc. is ideally positioned for sustainable growth.
Our vision at Biofrontera Inc. is to be a trusted partner who brings unparalleled therapies and service to patients and healthcare providers in the dermatology community.
Biofrontera Inc. will become a leading U.S. specialty dermatology company by focusing on innovative therapy options that enable dermatology healthcare professionals to help improve the lives of their patients.